High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-dose therapy with supporting autologous stem-cell transplantation remains a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited. METHODS: In this multicenter study, the Medical Research Council Myeloma VII Trial, we randomly assigned 407 patients with previously untreated multiple myeloma who were younger than 65 years of age to receive either standard conventional-dose combination chemotherapy or high-dose therapy and an autologous stem-cell transplant. RESULTS: Among the 401 patients who could be evaluated, the rates of complete response were higher in the intensive-therapy group than in the standard-therapy group (44 percent vs. 8 percent, P<0.001). The rates of partial response were similar (42 percent and 40 percent, respectively; P=0.72), and the rates of minimal response were lower in the intensive-therapy group than in the standard-therapy group (3 percent vs. 18 percent, P<0.001). Intention-to-treat analysis showed a higher rate of overall survival (P=0.04 by the log-rank test) and progression-free survival (P<0.001) in the intensive-therapy group than in the standard-therapy group. As compared with standard therapy, intensive treatment increased median survival by almost 1 year (54.1 months [95 percent confidence interval, 44.9 to 65.2] vs. 42.3 months [95 percent confidence interval, 33.1 to 51.6]). There was a trend toward a greater survival benefit in the group of patients with a poor prognosis, as defined by a high beta2-microglobulin level (more than 8 mg per liter). CONCLUSIONS: High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ASCT improves median OS in multiple myeloma by approximately 12 months.125–128”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [126]
Citations
Cites
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., et al. (1997) · Blood · doi:10.1182/blood.v89.3.789 · Cited by 541
HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA
MCELWAIN, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90739-0 · Cited by 510
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55.401k04_55_65 · Cited by 502
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Geneviève, F., Zandecki, M., Laı̈, J.-L., Leleu, X., Jouet, J.-P., Bauters, F., et al. (2001) · Blood · doi:10.1182/blood.v97.6.1566 · Cited by 312
Lenhoff, S., Hjorth, M., Holmberg, E. C., Turesson, I., Westin, J., Nielsen, J. L., Wislöff, F., Brinch, L., Carlson, K. E., Carlsson, M. S., et al. (2000) · PubMed · doi:10.1182/blood.v95.1.7 · Cited by 310
Research works printed but not linked: 7
- Morgan G, Selby P. Myeloma. In: Souhami R, Tannock I, Hohenberger P, Horiot J-C, eds. Oxford textbook of oncology. 2nd ed. Vol. 2. Oxford, England: Oxford University Press, 2001:2419-55.
- Lenhoff S, 2000, Blood, 95, 7
- Fermand J-P, 1999, Blood, 94, 396a
- Review manager (RevMan), version 4.1. Oxford, England: Cochrane Collaboration, 2000.
- Blade J, 2001, Blood, 98, 815a
- Segeren CM, 2001, Blood, 98, 815a
- Fermand J-P, 2001, Blood, 98, 815a
Cited by
Items 201–300 of 1,000
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma
Olin, R. L., Vogl, D. T., Porter, D., Luger, S. M., Schuster, S. J., Tsai, D. E., Siegel, D. L., Cook, R. J., Mangan, P. A., Cunningham, K., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.334 · Cited by 100
Impact of early relapse after auto-SCT for multiple myeloma
Kumar, S. K., Mahmood, S., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Buadi, F. K., Dingli, D., Rajkumar, S. V., Litzow, M. R., & Gertz, M. A. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.180 · Cited by 102
Jantunen, E., Kuittinen, T., Penttilä, K., Lehtonen, P., Mahlamäki, E., & Nousiainen, T. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705360 · Cited by 107
Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma
Yasui, H., Hideshima, T., Richardson, P. G., & Anderson, K. C. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05860.x · Cited by 98
“The median survival among patients treated with conventional chemotherapy is 3–4 years; although high-dose chemotherapy with stem cell support has significantly extended progressionfree and overall survival (Child et al, 2003), few, if any, patients are cured.”
BackgroundNiesvizky, R., Richardson, P. G., Rajkumar, S. V., Coleman, M., Rosiñol, L., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07303.x · Cited by 98
“…minimal response. research paper First published online 31 July 2008 ª 2008 The Authors doi:10.1111/j.1365-2141.2008.07303.x Journal Compilation ª 2008 Blackwell Publishing Ltd, British Journal of Haematology, 143, 46–53 survival (OS) (Attal et al, 1996; Barlogie et al, 1997; Child et al, 2003).”
BackgroundInfluentialPolymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma
Dasgupta, R. K., Adamson, P. J., Davies, F. E., Rollinson, S. J., Roddam, P. L., Ashcroft, A. J., Dring, A. M., Fenton, J. A. L., Child, J. A., Allan, J. M., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0444 · Cited by 103
Self-citationHsp90 Inhibitors in the Clinic
Pacey, S., Banerj, U., Judson, I. R., & Workman, P. (2005) · Springer eBooks · doi:10.1007/3-540-29717-0_14 · Cited by 109
“Until recently, attempts to prolong survival were limited to patients fit enough to undergo high-dose chemotherapy with stem cell rescue (Child et al. 2003).”
BackgroundPalumbo, A., Bringhen, S., Bruno, B., Falcone, A. P., Liberati, A. M., Grasso, M., Ria, R., Pisani, F., Cangialosi, C., Caravita, T., et al. (2009) · Blood · doi:10.1182/blood-2009-09-241737 · Cited by 105
“(%) IgG 88 (59) 83 (56) IgA 33 (22) 42 (28) Bence Jones protein 27 (18) 21 (14) Other 0 (0) 3 (2) Hemoglobin”
Bruno, B., Rotta, M., Patriarca, F. F., Mattei, D. G., Allione, B., Carnevale‐Schianca, F., Sorasio, R., Rambaldi, A., Casini, M., Parma, M., et al. (2008) · Blood · doi:10.1182/blood-2008-07-167379 · Cited by 100
“Male 52 (52) 52 (54) Mean age, y (range) 54 (30-65) 54 (30-65) Durie & Salmon stage II 29 (29) 26 ( 27 ) Durie & Salmon stage III 67 (67) 66 (69) International Staging System 2 22/92 (24) 22/88 (25) International Staging System 3 14/92 (15) 12/88 (14) IgG myeloma 57 (57) 56 (58) IgA myeloma 18 (18) 18 (19) IgD myeloma…”
InfluentialSundaresan, N., Boriani, S., Rothman, A., & Holtzman, R. N. N. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000041888.33499.03 · Cited by 96
“Recent advances including the use of autologous hematopoietic stem cell rescue produces complete response rates of 50%, with mortality rates of less than 3% [40].”
Knop, S. T., Straka, C., Haen, M., Schwedes, R., Hebart, H. F., & Einsele, H. (2005) · PubMed · Cited by 99
Auner, H. W., Iacobelli, S., Sbianchi, G., Knol, C., Blaise, D., Russell, N. H., Apperley, J. F., Pohlreich, D., Browne, P., Kobbe, G., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.181339 · Cited by 106
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma
Kumar, S. K., Witzig, T. E., Dispenzieri, A. A., Lacy, M. Q., Wellik, L. E., Fonseca, R., Lust, J. A., Gertz, M. A., Kyle, R. A., Greipp, P. R., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403285 · Cited by 100
Multiple Myeloma in the Older Adult: Better Prospects, More Challenges
Wildes, T. M., Rosko, A. E., & Tuchman, S. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1028 · Cited by 98
Moreau, P., Hulin, C., Garban, F., Yakoub‐Agha, I., Benboubker, L., Attal, M., Marit, G., Fuzibet, J., Doyen, C., Voillat, L., et al. (2005) · Blood · doi:10.1182/blood-2005-06-2573 · Cited by 101
“CRP level, mg/L (range) 6 (1-279) 7 (1-244) 5 (1-137) .”
BackgroundKumar, S. K., Lacy, M. Q., Dispenzieri, A. A., Rajkumar, S. V., Fonseca, R., Geyer, S. M., Allmer, C., Witzig, T. E., Lust, J. A., Greipp, P. R., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704545 · Cited by 96
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
Ludwig, H., Beksaç, M., Bladé, J., Boccadoro, M., Cavenagh, J. D., Cavo, M., Dimopoulos, M. A., Drach, J. W., Einsele, H., Facon, T. T. F., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0203 · Cited by 108
Self-citationDrayson, M. T., Begum, G., Basu, S., Makkuni, S., Dunn, J., Barth, N. J., & Child, J. A. (2006) · Blood · doi:10.1182/blood-2006-03-008953 · Cited by 94
Self-citationKobune, M., Chiba, H., Kato, J., Kato, K., Nakamura, K., Kawano, Y., Takada, K., Takimoto, R., Takayama, T., Hamada, H., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0684 · Cited by 92
Quantification of clonal circulating plasma cells in relapsed multiple myeloma
Gonsalves, W. I., Morice, W. G., Rajkumar, S. V., Gupta, V. K., Timm, M., Dispenzieri, A. A., Buadi, F. K., Lacy, M. Q., Singh, P. P., Kapoor, P., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13067 · Cited by 98
“…as immunomodulatory drugs and proteasome inhibitors (Kumar et al, 2008a), as well as high dose chemotherapy followed by autologous stem cell transplantation (ASCT) in eligible patients (Attal et al, 1996; Child et al, 2003) has improved the survival outcomes for MM patients over the last decade.”
Efficacy of Panobinostat for the Treatment of Multiple Myeloma
Eleutherakis‐Papaiakovou, E., Kanellias, N., Kastritis, E., Gavriatopoulou, M., Terpos, E., & Dimopoulos, M. A. (2020) · Journal of Oncology · doi:10.1155/2020/7131802 · Cited by 97
Mesguich, C., Fardanesh, R., Tanenbaum, L. N., Chari, A., Jagannath, S., & Kostakoğlu, L. (2014) · European Journal of Radiology · doi:10.1016/j.ejrad.2014.09.012 · Cited by 95
Moreau, P., Attal, M., Garban, F., Hulin, C., Facon, T. T. F., Marit, G., Michallet, M., Doyen, C., Leyvraz, S., Mohty, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404832 · Cited by 97
Advances in Biology and Therapy of Multiple Myeloma
Barillé-Nion, S., Barlogie, B., Bataille, R., Bergsagel, P. L., Epstein, J., Fenton, R. G., Jacobson, J., Kuehl, W. M., Shaughnessy, J., & Tricot, G. (2003) · Hematology · doi:10.1182/asheducation-2003.1.248 · Cited by 93
Dingli, D., Nowakowski, G. S., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Litzow, M. R., Gastineau, D. A., & Gertz, M. A. (2006) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2006.n.014 · Cited by 92
Rapoport, A. P., Stadtmauer, E. A., Aqui, N., Vogl, D., Chew, A., Fang, H.-B., Janofsky, S., Yager, K., Veloso, E., Zheng, Z., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0418 · Cited by 90
Transplantation for multiple myeloma: who, when, how often?
(2003) · Blood · doi:10.1182/blood-2003-01-0073 · Cited by 88
Peled, A., Abraham, M., Avivi, I., Rowe, J. M., Beider, K., Wald, H., Tiomkin, L., Ribakovsky, L., Riback, Y., Ramati, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1302 · Cited by 87
“High-dose chemotherapy in conjunction with autologous stem cell transplantation (ASCT) has emerged as an established treatment modality for a variety of hematologic malignancies, including multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL) (1, 2).”
BackgroundCrees, Z. D., Rettig, M. P., Jayasinghe, R. G., Stockerl-Goldstein, K. E., Larson, S. M., Árpád, I., Milone, G. A., Martino, M. V., Stiff, P. J., Sborov, D. W., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02273-z · Cited by 90
Tricot, G. J. K., Cottler‐Fox, M., & Calandra, G. C. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.130 · Cited by 91
Outcome of autologous stem cell transplantation for AL amyloidosis in the UK
Goodman, H. J. B., Gillmore, J. D., Lachmann, H. J., Wechalekar, A. D., Bradwell, A. R., & Hawkins, P. N. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06204.x · Cited by 88
“Even in uncomplicated myeloma, TRM during SCT is 1–2% in clinical trial populations (Child et al, 2003), and up to 5% overall (Reece et al, 2003).”
BackgroundOlder Patients with Myeloma Derive Similar Benefit from Autologous Transplantation
Sharma, M. R., Zhang, M., Zhong, X., Abidi, M. H., Akpek, G., Bacher, U., Callander, N. S., Dispenzieri, A. A., Freytes, C. O., Fung, H. C. H., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.07.013 · Cited by 84
“Randomized studies confirm the benefit of autologous transplantation in subjects 65 years of age, but these studies typically excluded older subjects [4,5].”
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma
Palumbo, A., Bertola, A., Musto, P., Caravita, T., Callea, V., Nunzi, M., Grasso, M., Falco, P., Cangialosi, C., & Boccadoro, M. (2005) · Cancer · doi:10.1002/cncr.21342 · Cited by 88
Development of novel CXCR4-based therapeutics
Peled, A., Wald, O., & Burger, J. A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.656197 · Cited by 91
“One of the main factors that determine the success of engraftment is the number of CD34 cells used for transplantation [99,100].”
BackgroundKhanim, F. L., Merrick, B. A. M. E., Giles, H. V., Jankute, M., Jackson, J. B., Giles, L. J., Birtwistle, J., Bunce, C. M., & Drayson, M. T. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.38 · Cited by 83
Self-citationCosta, L. J., Huang, J.-X., & Hari, P. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.12.024 · Cited by 84
“When employed early in the management of MM in younger patients, AHCT prolongs both the depth and duration of response and, in some studies, overall survival [1,2].”
Steidl, U. G., Fenk, R. R., Bruns, I., Neumann, F., Kondakci, M., Hoyer, B., Graef, T. T., Rohr, U.-P., Bork, S., Kronenwett, R., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704702 · Cited by 88
Patriarca, F. F., Einsele, H., Spina, F., Bruno, B., Isola, M., Nozzoli, C., Nozza, A., Sperotto, A. A., Morabito, F., Stuhler, G., et al. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.07.026 · Cited by 84
Khan, N., Lindner, S., Gomes, A. L. C., Devlin, S. M., Shah, G. L., Sung, A. D., Sauter, C. S., Landau, H. J., Dahi, P. B., Perales, M., et al. (2020) · Blood · doi:10.1182/blood.2020006923 · Cited by 86
Shustik, C., Belch, A. R., Robinson, S., Rubin, S. H., Dolan, S., Kovacs, M. J., Grewal, K. S., Walde, D., Barr, R., Wilson, J., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06405.x · Cited by 83
“…autologous stem cell transplantation has become the standard of care for many patients with multiple myeloma (Attal et al, 1996; Imrie et al, 2002; Child et al, 2003), randomised trials have largely excluded patients with important co-morbidities and those older than 65 years, the median age of…”
BackgroundSheppard, D., Bredeson, C., Allan, D., & Tay, J. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.01.008 · Cited by 85
“High-dose chemotherapy, supported by autologous hematopoietic stem cell transplantation (HSCT), is an effective treatment strategy for a variety of hematologic malignancies [1-4].”
BackgroundSonneveld, P., van der Holt, B., Segeren, C. M., Vellenga, E., Croockewit, A. J., Verhoef, G., Cornelissen, J. J., Schaafsma, M. R., van Oers, M. H. J., Wijermans, P., et al. (2007) · Haematologica · doi:10.3324/haematol.11168 · Cited by 87
Harousseau, J., Shaughnessy, J. D., & Richardson, P. G. G. (2004) · Hematology · doi:10.1182/asheducation-2004.1.237 · Cited by 106
Parikh, G. C., Amjad, A. I., Saliba, R. M., Kazmi, S. M. A., Khan, Z. U., Lahoti, A., Hosing, C. M., Mendoza, F. L., Qureshi, S. R., Weber, D. M., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.03.021 · Cited by 82
Bakkus, M. H. C., Bouko, Y., Samson, D., Apperley, J. F., Thielemans, K., Camp, B. V., Benner, A., Goldschmidt, H., Moos, M., & Cremer, F. W. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05120.x · Cited by 81
“…is a prognostic parameter in multiple myeloma High-dose therapy (HDT) followed by transplantation of autologous bone marrow (BM) or peripheral blood stem cells (PBSCT) prolongs remission duration and survival (OS) when compared with conventional treatment (Attal et al, 1996; Child et al, 2003).”
BackgroundNojima, M., Maruyama, R., Yasui, H., Suzuki, H., Maruyama, Y., Tarasawa, I., Sasaki, Y., Asaoku, H., Sakai, H., Hayashi, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3336 · Cited by 84
“combined with stem cell transplantation (1).”
Dingli, D., Nowakowski, G. S., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Rajkumar, S. V., Greipp, P. R., Litzow, M. R., Gastineau, D. A., Witzig, T. E., et al. (2005) · Blood · doi:10.1182/blood-2005-08-3398 · Cited by 85
New investigational drugs with single-agent activity in multiple myeloma
Rajan, A. M., & Kumar, S. K. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.53 · Cited by 81
Avet-Loiseau, H. (2010) · Hematology · doi:10.1182/asheducation-2010.1.489 · Cited by 77
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma
Raje, N. S., Hideshima, T., Davies, F. E., Chauhan, D., Treon, S. P., Young, G. Q., Tai, Y., Avigan, D., Gong, J., Schlossman, R. L., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04929.x · Cited by 80
“…randomized trial, the Intergroupe Francais du Myeloma (Attal et al, 1996) and more recently, the Medical Research Council Myeloma VII trial (Child et al, 2003) have clearly demonstrated the benefits of autologous peripheral blood (PB) stem cell transplantation over conventional…”
BackgroundSelf-citationPalumbo, A. P., Attal, M., & Roussel, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1925 · Cited by 82
Gahrton, G., Iacobelli, S., Apperley, J. F., Bandini, G., Björkstrand, B., Bladé, J., Boiron, J.-M., Cavo, M., Cornelissen, J. J., Corradini, P., et al. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704861 · Cited by 82
Zeiser, R., Deschler-Baier, B., Bertz, H., Finke, J., & Engelhardt, M. M. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704713 · Cited by 81
Blanes, M., Lahuerta, J. J., González, J. D., Ribas, P., Solano, C., Alegre, A. M., Bladé, J., Miguel, J. F. S., Sanz, M. Á., & de la Rubia, J. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.08.009 · Cited by 78
“6 months) [3,6,31,32] and is similar to trials including a double tandem transplantation approach with MEL-only preparative regimens [33e35].”
BackgroundResultQazilbash, M. H., Saliba, R. M., Lima, M. J. G. D., Hosing, C. M., Couriel, D. R., Aleman, A., Roden, L., Champlin, R. E., & Giralt, S. (2006) · Cancer · doi:10.1002/cncr.21700 · Cited by 76
Kumar, S. K., Gertz, M. A., Dispenzieri, A. A., Lacy, M. Q., Wellik, L. E., Fonseca, R., Lust, J. A., Witzig, T. E., Kyle, R. A., Greipp, P. R., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704555 · Cited by 83
Treatment of Myeloma: Cure vs Control
Rajkumar, S. V. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.10.1142 · Cited by 73
Emerging therapies for the treatment of relapsed or refractory multiple myeloma
Dimopoulos, M. A., Miguel, J. F. S., & Anderson, K. C. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01542.x · Cited by 79
“Newly diagnosed MM is responsive to treatment with combinations of melphalan, prednisone, dexamethasone, doxorubicin, immunomodulatory drugs (IMiDs; such as thalidomide and lenalidomide), and proteasome inhibitors (PIs, such as bortezomib) (3) or autologous stem cell transplant following high-dose chemotherapy in appr…”
BackgroundInfluentialKovacs, M. J., Reece, D. E., Marcellus, D. C., Meyer, R. M., Mathews, S., Dong, R.-P., & Eisenhauer, E. A. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9022-7 · Cited by 77
Barlogie, B., Tricot, G. J. K., Haessler, J., van Rhee, F., Cottler‐Fox, M., Anaissie, E. J., Waldron, J. A., Pineda‐Roman, M., Thertulien, R., Zangari, M., et al. (2007) · Blood · doi:10.1182/blood-2007-06-097444 · Cited by 78
“All 105 patients* Total CD34 collected less than 3 106/kg 57/2313 (2) 3.”
Sherman, A. C., Simonton, S., Latif, U., Spohn, R., & Tricot, G. J. K. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704465 · Cited by 84
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
Farag, S. S., Zhang, S., Jansak, B. S., Wang, X., Kraut, E. H., Chan, K. K., Dancey, J. E., & Grever, M. R. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.01.039 · Cited by 75
“Although igh-dose chemotherapy has improved long-termoutcome, almost ll patients still relapse [1,2].”
BackgroundDurable remission with salvage second autotransplants in patients with multiple myeloma
Shah, N., Ahmed, F., Bashir, Q., Qureshi, S., Dinh, Y. T., Rondón, G., Wen, S., Thall, P. F., Khan, H. M., Giralt, S., et al. (2011) · Cancer · doi:10.1002/cncr.26662 · Cited by 78
Multiple Myeloma, Version 2.2016
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C. L., Djulbegović, B., Fung, H. C. H., Gasparetto, C., Godby, K. N., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0167 · Cited by 85
Hamadani, M., Kochuparambil, S. T., Osman, S., Cumpston, A., Leadmon, S., Bunner, P., Watkins, K., Morrison, D. D., Speir, E. J., DeRemer, D. L., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.01.005 · Cited by 76
Lenhoff, S., Hjorth, M., Westin, J., Brinch, L., Bäckström, B., Carlson, K. E., Christiansen, I., Dahl, I. M. S., Gimsing, P., Hammerstrøm, J., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06042.x · Cited by 76
“The results clearly indicated that high-dose therapy is superior to conventional therapy in younger patients (Attal et al, 1996; Barlogie et al, 1997; Fermand et al, 1998; Child et al, 2003).”
BackgroundResultDunavin, N., Wei, L., Elder, P., Phillips, G. S., Benson, D. M., Hofmeister, C. C., Penza, S. L., Greenfield, C. N., Rose, K. S., Rieser, G., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.751528 · Cited by 75
Hicks, L. K., Haynes, A. E., Reece, D. E., Walker, I., Herst, J. A., Meyer, R. M., & Imrie, K. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.02.003 · Cited by 82
“High dose melphalan with autologous stem cell transplantation (ASCT) improves overall survival in patients with myeloma who are less than 65 years of age.(2,3) However, because myeloma is predominantly a disease of older patients,(4) transplantation is an option for only approximately 50% of patients with myeloma.”
BackgroundWeichman, K. I., Dember, L. M., Prokaeva, T. B., Wright, D. G., Quillen, K., Rosenzweig, M. A., Skinner, M. M., Seldin, D. C., & Sanchorawala, V. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705447 · Cited by 73
Vij, R., Kumar, S. K., Zhang, M., Zhong, X., Huang, J., Dispenzieri, A. A., Abidi, M. H., Bird, J. M., Freytes, C. O., Gale, R. P., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.10.023 · Cited by 75
“Time from diagnosis to HCT, median (range) 7 (2-12) 8 (3-12)”
Costa, L. J., Miller, A. N., Alexander, E. T., Hogan, K. R., Shabbir, M., Schaub, C., & Stuart, R. K. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.170 · Cited by 72
Hobo, W. A., Strobbe, L. S., Maas, F., Fredrix, H., Greupink-Draaisma, A., Esendam, B., de Witte, T., Preijers, F. W. M. B., Levenga, H., van Rees, B. P., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1438-2 · Cited by 76
Armeson, K. E., Hill, E. G., & Costa, L. J. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.173 · Cited by 74
Bashir, Q., Shah, N. D., Parmar, S., Wei, W., Rondón, G., Weber, D. M., Wang, M. L., Orlowski, R. Z., Thomas, S. K., Shah, J. J., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.606942 · Cited by 74
“Several studies have highlighted the effi cacy of high-dose therapy followed by auto HCT with a signifi cant improvement in complete response (CR) rate, progression-free survival (PFS) and overall survival (OS) when compared to conventional therapy [2,3].”
Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma
Lemieux‐Blanchard, É., Hulin, C., Caillot, D., Tardy, S., Dorvaux, V., Michel, J., Gastinne, T., Rossi, C., Legouge, C., Touzeau, C., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.11.013 · Cited by 72
“INTRODUCTION dexamethasone achieved superior results compared with Autologous stem cell transplantation (ASCT) after highdose melphalan is the treatment of choice for patients with symptomatic multiple myeloma (MM) who are younger than 65 years of age [1,2].”
BackgroundAnti-angiogenesis therapies: their potential in cancer management
Gaya, A. M., Eichholz, A., & Merchant (2010) · OncoTargets and Therapy · doi:10.2147/ott.s5256 · Cited by 83
“Combination with dexamethasone In patients with myeloma, trials have shown that chemotherapy followed by stem cell transplantation provides the best overall survival for suitable patients.(68,69) Thalidomide with dexamethasone is now accepted as an effective induction therapy for newly diagnosed myeloma patients who a…”
Razavi, P., Rand, K. A., Cozen, W., Chanan-Khan, A. A., Usmani, S. Z., & Ailawadhi, S. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.19 · Cited by 73
Rajkumar, S. V. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.01.001 · Cited by 94
Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation
Donato, M. L., Feasel, A. M., Weber, D. M., Prieto, V. G., Giralt, S., Champlin, R. E., & Duvic, M. A. (2005) · Blood · doi:10.1182/blood-2004-12-4870 · Cited by 70
Gaul, L., Mandl–Weber, S., Baumann, P., Emmerich, B., & Schmidmaier, R. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0278-x · Cited by 71
“Only dose escalation of melphalan, enabled by the technology of autologous stem cell transplantation to overcome haematotoxicity, signiWcantly improves overall survival (Child et al. 2003; Attal et al. 1996).”
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment
Magen, H., & Muchtar, E. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716652862 · Cited by 77
Multiple myeloma: Role of autologous transplantation
Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101929 · Cited by 74
“The cardinal randomised clinical trials by the IFM and the United Kingdom Medical Research Council (MRC) provided a strong rationale for the universal incorporation of ASCT in MM therapeutics in late 90s and early 00s [7,10].”
BackgroundLee, S. J., Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Miguel, J. F. S., Crawford, B., Massaro, J. M., Dhawan, R., Gupta, S. K., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07378.x · Cited by 72
“Front-line therapies include induction therapy followed by high-dose chemotherapy with stem-cell transplantation (Attal et al, 2003; Child et al, 2003; Fermand et al, 2005; Barlogie et al, 2006) or conventional chemotherapy.”
BackgroundSinha, S., Gastineau, D. A., Micallef, I. N., Hogan, W. J., Ansell, S. M., Buadi, F. K., Dingli, D., Dispenzieri, A. A., Gertz, M. A., Greiner, C. W., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.236 · Cited by 74
Terpos, E., Rezvani, K., Basu, S., Milne, A., Rose, P. E., Scott, G. L., Rahemtulla, A., Samson, D., & Apperley, J. F. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00531.x · Cited by 69
Spencer, A. G., Horvath, N., Gibson, J., Prince, H. M., Herrmann, R., Bashford, J., Joske, D. J. L., Grigg, A., McKendrick, J., Prosser, I. W., et al. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704946 · Cited by 71
Campigotto, F., & Weller, E. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.6340 · Cited by 77
Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
de Lavallade, H., Cheikh, J. E., Faucher, C., Fürst, S., Am, S., Coso, D., Bouabdallah, R., Chabannon, C., Gastaut, J. A., Blaise, D., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.22 · Cited by 69
Bruns, I., Steidl, U. G., Kronenwett, R., Fenk, R. R., Graef, T. T., Rohr, U., Neumann, F., Fischer, J., Scheid, C., Hübel, K., et al. (2005) · Transfusion · doi:10.1111/j.1537-2995.2006.00699.x · Cited by 69
“Variable Pegfilgrastim group G-CSF group 6 mg 12 mg Day of first apheresis procedure† 12 (11-19) 13 (11-15) 15 (12-18) Number of apheresis procedures 1 (1-3) 1 (1-2) 1 Processed volume (L) 10.”
BackgroundMohty, M., Boiron, J.-M., Damaj, G. L., Michallet, A., Bay, J., Faucher, C., Perreau, V., Bilger, K., Coso, D., Stoppa, A., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704531 · Cited by 70
Chhabra, S., Callander, N. S., Watts, N., Costa, L. J., Thapa, B., Kaufman, J. L., Laubach, J. P., Sborov, D. W., Reeves, B., Rodriguez, C., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.11.029 · Cited by 74
Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Kumar, S. K., Leung, N., & Gastineau, D. A. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705627 · Cited by 67
Second auto-SCT for treatment of relapsed multiple myeloma
Gonsalves, W. I., Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Buadi, F. K., Dingli, D., Hogan, W. J., & Kumar, S. K. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.183 · Cited by 67
Terpos, E., Politou, M., Szydlo, R., Nadal, E., Avery, S., Olavarría, E., Kanfer, E., Goldman, J. M., Apperley, J. F., & Rahemtulla, A. (2004) · Leukemia · doi:10.1038/sj.leu.2403423 · Cited by 67
Mohty, M., & Harousseau, J. (2014) · Haematologica · doi:10.3324/haematol.2013.096149 · Cited by 70
“These findings were confirmed seven years later in a larger study conducted by the UK Medical Research Council (MRC Myeloma VII trial).(2) Following these results, HDT/ASCT became the standard of care in patients without severe comorbidities and under 65 years of age.”
ResultPineda‐Roman, M., Bolejack, V., Arzoumanian, V., Anaissie, E., Van Rhee, F., Zangari, M., Walker, R., Hollmig, K., Shaughnessy, J. D., Epstein, J., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06441.x · Cited by 66
“…has been extended beyond 6 years, presumably as a result of profound tumour cytoreduction (Barlogie et al, 1999) reflected by complete response (CR) rates of 20% with single and 40% with tandem transplants (Attal et al, 1996; Attal et al, 2003; Child et al, 2003; Barlogie et al, 2005, 2006).”
BackgroundRace and Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Hari, P., Majhail, N. S., Zhang, M., Hassebroek, A. M., Siddiqui, F., Ballen, K. K., Bashey, A., Bird, J. M., Freytes, C. O., Gibson, J., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.11.007 · Cited by 64
“Randomized clinical trials support the use of autologous hematopoietic-cell transplant (AHCT) as a standard therapy for MM [17,18].”
BackgroundMahindra, A. K., Hari, P., Fraser, R. A., Fei, M., Huang, J., Berdeja, J. G., Callander, N. S., Costa, L. J., Díaz, M. Á., Freytes, C. O., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.198 · Cited by 67
“The median (range) inpatient hospital stay was 14 days (1-90) in patients with normal/mild, 16 (3-77) in patients with moderate and 17 (4-70) in patients with severe RI.”
BackgroundWatanabe, M., Dewan, M. Z., Okamura, T., Sasaki, M., Itoh, K., Higashihara, M., Mizoguchi, H., Honda, M., Sata, T., Watanabe, T., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20688 · Cited by 65
Epidemiology and outcomes research for MGUS, myeloma and amyloidosis
Sirohi, B., & Powles, R. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.065 · Cited by 72
Metadata
- Authors
- Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J.
- Affiliations
- University of Leeds (GB)
- University of Birmingham (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-05-08
- Volume
- 348
- Issue
- 19
- Pages
- 1875-1883
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102591890
- Semantic Scholar
- 5d90e1ff237e9db8f41e6e1e264450eed3f77e40
- Cited by
- 1,768
- References
- 23
- Citations by year
- 2026: 17 · 2025: 26 · 2024: 34 · 2023: 36 · 2022: 41 · 2021: 57 · 2020: 83 · 2019: 46 · 2018: 71 · 2017: 76 · 2016: 73 · 2015: 71 · 2014: 81 · 2013: 103 · 2012: 94
- FWCI
- 53.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, high-dose chemotherapy, autologous stem cell transplantation, first-line therapy, complete response, overall survival, progression-free survival, beta2-microglobulin, prognostic factors, previously untreated myeloma
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carmustine, Cause of Death, Combined Modality Therapy, Cyclophosphamide, Doxorubicin, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prognosis, Survival Analysis, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Alkylating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.